Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print New-generation Antipsychotic Drugs May Have Similar Neurological Side-effects To Conventional Drugs (p 1581)

New-generation Antipsychotic Drugs May Have Similar Neurological Side-effects To Conventional Drugs (p 1581)

May 07, 2003

Authors of a systematic review of antipsychotic drugs in this week's issue of THE LANCET highlight how the better side-effect profile of new-generation drugs may not be as substantial as previously thought when compared with conventional antipsychotics.

New-generation drugs are generally more efficacious, although older-generation antipsychotics are still a cost-effective option for treating disorders such as schizophrenia in resource-poor settings.

The main advantage of new-generation antipsychotic drugs is a reduced risk of side-effects compared with conventional drugs. However, there is debate that the reduced side-effects of the new-generation class of drugs is based on trials that could have been biased due to comparisons with the high-potency antipsychotic drug haloperidol.

Stefan Leucht from the Zucker Hillside Hospital, New York, USA, and colleagues reanalysed all previous randomised controlled trials where new-generation antipsychotics had been compared with low-potency conventional drugs.

31 studies which involved 2320 patients were identified. Of the new generation drugs, only clozapine was associated with fewer neurological side-effects and higher efficacy than low-potency conventional drugs. As a group, new-generation drugs were moderately more efficacious than low-potency antipsychotics.

Stefan Leucht comments: "Optimum doses of low-potency conventional antipsychotics might not induce more neurological side-effects than new generation drugs. Potential advantages in efficacy of the new-generation drugs should be a factor in clinical treatment decisions to use these rather than conventional drugs. However, if these findings are confirmed by future studies, there would be a good argument for the use of appropriately dosed conventional drugs-such as chlorpromazine-for patients with schizophrenia in settings where new-generation drugs are not generally affordable."

Lancet




Related Schizophrenia News Articles Schizophrenia News and Current Schizophrenia Events RSS Schizophrenia News and Current Schizophrenia Events RSS
Severe, acute maternal stress linked to the development of schizophrenia
Pregnant women who endure the psychological stress of being in a war zone are more likely to give birth to a child who develops schizophrenia.

Unlocking mystery of why dopamine freezes Parkinson's patients
Parkinson's disease and drug addiction are polar opposite diseases, but both depend upon dopamine in the brain. Parkinson's patients don't have enough of it; drug addicts get too much of it. Although the importance of dopamine in these disorders has been well known, the way it works has been a mystery.

Human brains pay a price for being big
Metabolic changes responsible for the evolution of our unique cognitive abilities indicate that the brain may have been pushed to the limit of its capabilities. Research published today in BioMed Central's open access journal Genome Biology adds weight to the theory that schizophrenia is a costly by-product of human brain evolution.

Estrogen relieves psychotic symptoms in women with schizophrenia
When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.

Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time.

Protein marker for schizophrenia risk
A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics.

Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Violence declines with medication use in some with schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.

NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression
New findings from research supported by NARSAD, the world's leading charity dedicated to mental health research, and conducted by Harvard-affiliated scientists are providing important clues into how genes work to impair various aspects of attention, memory and perception -- the behaviors associated with many psychiatric illnesses, such as schizophrenia, bipolar disorder and depression.
More Schizophrenia News Articles


The Soloist: A Lost Dream, an Unlikely Friendship, and the Redemptive Power of Music
by Steve Lopez

A moving story of the remarkable bond between a journalist in search of a story and a homeless, classically trained musician—destined to be a major motion picture from DreamWorks, starring Jamie Foxx and Robert Downey Jr.When Steve Lopez saw Nathaniel Ayers playing his heart out on a two-string violin on Los Angeles’ skid row, he found it impossible to walk away. More than thirty years earlier,...



Abnormal Psychology (5th Edition)
by Thomas F. Oltmanns, Robert E. Emery

This new edition retains the book's engaging and innovative systems approach, integrating the biological, psychological, and social perspectives in one concurrent story. Scientific methods are presented in a clear and non-threatening manner, and are based on the most current research. Chapter topics include personality disorders, eating disorders, substance use disorders, sexual and gender...



Center Cannot Hold, The: My Journey Through Madness
by Elyn R. Saks

Elyn Saks is a success by any measure: she's an endowed professor at the prestigious University of Southern California Gould School of Law. She has managed to achieve this in spite of being diagnosed as schizophrenic and given a "grave" prognosis -- and suffering the effects of her illness throughout her life.Saks was only eight, and living an otherwise idyllic childhood in sunny 1960s Miami,...



The Quiet Room: A Journey Out of the Torment of Madness
by Lori Schiller, Amanda Bennett



Mad In America: Bad Science, Bad Medicine, and The Enduring Mistreatment of the Mentally Ill
by Robert Whitaker

Hot on the heels of an optimistic film about Nobelist John Nash's schizophrenic journey comes medical journalist Robert Whitaker's disturbing exposé of the cruel and corrupt business of treating mental illness in America. Mad in America begins by surveying three centuries of mental health treatments to discover why positive outcomes for schizophrenics in the U.S. for the last 25 years have...



Surviving Schizophrenia: A Manual for Families, Consumers, and Providers (4th Edition)
by E. Fuller Torrey

The third edition of this indispensable manual thoroughly details everything patients, families, and mental health professionals need to know about one of the most widespread and misunderstood...



A Thousand Plateaus: Capitalism and Schizophrenia
by Gilles Deleuze, Felix Guattari, Brian Massumi



Gut and Psychology Syndrome: Natural Treatment for Autism,ADD/ADHD,Dyslexia,Dyspraxia,Depression,Schizophrenia
by Dr. Natasha Campbell-McBride MD

Book Description Dr. Natasha Campbell-McBride set up The Cambridge Nutrition Clinic in 1998. As a parent of a child diagnosed with learning disabilities, she was acutely aware of the difficulties facing other parents like her, and she has devoted much of her time to helping these families. She realised that nutrition played a critical role in helping children and adults to overcome their...



Nutrition and Mental Illness: An Orthomolecular Approach to Balancing Body Chemistry
by Carl C. Pfeiffer

Believing that drugs and psychoanalysis were not always the best course of treatment for a variety of mental illnesses, Dr. Carl Pfeiffer began an extensive program of research into the causes and treatment of mental illness, and in 1973 opened the Brain Bio Center in Princeton, New Jersey. Here, with a team of scientists, he found that many psychological problems can be traced to biochemical...



Abnormal Psychology in a Changing World
by Jeffrey S. Nevid, Spence A. Rathus, Beverly Greene

This introduction to abnormal psychology is designed to make the material more accessible and inviting to a new generation in a changing world. Noteworthy for its clear and engaging writing style that is accessible to readers, superior pedagogy, many engaging case examples and user-oriented applications, and integration of sociocultural material throughout. The authors adopt an interactionist...

© 2008 BrightSurf.com